Good Use of Normal Human ImmunoGlobulins (NHIg): Feasibility of Integrating the Criteria of Hierarchy During of NHIg Dispensations

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Supply of Normal Human Immunoglobulins (NHIg) has been in steady tension for almost 15 years in the world. The scarcity of raw material, manufacturing time by industries, and increase consumptions are some of the causes. These phenomena has been accentuated for two years in the context of pandemic.

Faced these difficulties, the french National Medication Security Agency (ANSM) , in collaboration with health professionals and patients associations concerned, established a hierarchy of indications of NHIg to prioritize NHIg for patients without therapeutic alternative (2013 and 2019). Its use is sometimes complex, particularly in the indications where the use of NHIg must combine clinico-biological criteria and/or previous treatment lines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia

NCT02881437

Primary Immunodeficiency

COMPLETED PHASE4

COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

NCT04555148

Covid19

COMPLETED PHASE2

Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome

NCT04550611

Guillain-Barre Syndrome

UNKNOWN NA

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

NCT00542997

Common Variable Immunodeficiency X-linked Agammaglobulinemia Autosomal Recessive Agammaglobulinemia

COMPLETED PHASE3

Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy

NCT00195637

Hereditary Inclusion Body Myopathy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunoglobulins

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients treated with NHIg

Patients treated for one of the following indications :

* Thrombopenic Idiopathic Purpura (TIP)
* Chronic Demyelinating Inflammatory Polyradiculoneuritis (CDIP)
* Secondary immune deficiency (SID)

NHIg prescription

Intervention Type OTHER

Analysis of NHIg prescription

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NHIg prescription

Analysis of NHIg prescription

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients treated with NHIg for one of the following 3 indications between 01/10/2021 and 31/12/2021: TIP, CDIP and SID.
* Patients 18 years of age and older